Prolonged Neutropenia after Sunitinib Treatment in a Patient with a Glucagonoma and Multiple Hepatic Metastases.
10.3904/kjm.2013.84.3.405
- Author:
Hong Ran MOON
1
;
Ji Min CHOI
;
Dong Kee JANG
;
Minjong LEE
Author Information
1. Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea. leejemj2@snu.ac.kr
- Publication Type:Case Report
- Keywords:
Pancreas;
Neuroendocrine tumors;
Glucagonoma;
Sunitinib;
Neutropenia
- MeSH:
Anemia;
Asian Continental Ancestry Group;
Diabetes Mellitus;
Female;
Glucagonoma;
Humans;
Indoles;
Liver;
Lymph Nodes;
Necrolytic Migratory Erythema;
Neoplasm Metastasis;
Neuroectodermal Tumors, Primitive;
Neuroendocrine Tumors;
Neutropenia;
Pancreas;
Paraneoplastic Syndromes;
Pyrroles;
Weight Loss
- From:Korean Journal of Medicine
2013;84(3):405-410
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Pancreatic neuroendocrine tumors (PNET) are rare, with approximately 2.2 in 1,000,000 people affected annually. In the classification of neuroendocrine tumors, glucagonomas are a functional PNET and comprise 1.6% of PNET. Glucagonoma syndrome is a paraneoplastic syndrome that is characterized by necrolytic migratory erythema, weight loss, anemia, and diabetes mellitus. Metastatic disease at presentation is common, but is often limited to the liver and regional lymph nodes. Sunitinib malate improves the progression-free and overall survival of PNET. This report presents a 45-year-old Asian woman with prolonged neutropenia after sunitinib treatment of a glucagonoma with multiple hepatic metastases. The severity of the neutropenia after the sunitinib treatment fluctuated from grade 1 to 4 repeatedly, with a non-febrile pattern. Ultimately, the patient did not recover from the neutropenia, even after stopping the sunitinib.
